Hepatitis D Market to Observe Stunning Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Key Companies - Eiger Biopharmaceuticals, Arrowhead Pharma, Antios, PharmaEssentia, REPLICor, SomaGenics, Vir Biotechnology, VLP Biotech

The Hepatitis D Market size in the 7MM was found to be USD 650 million in 2022, which is anticipated to grow by 2032. As per DelveInsight, the Hepatitis D Market is anticipated to evolve immensely in the coming years owing to the increase in the prevalent pool, rising awareness, the anticipated launch of premium price therapies, an increase in healthcare access, and an increase in scientific research and interest.

DelveInsight's "Hepatitis D Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hepatitis D Market Size and Share in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The market report covers emerging drugs, treatment practices, market share of individual Hepatitis D therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Hepatitis D treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.

Hepatitis D: An Overview
According to World Health Organization (WHO), Hepatitis D virus (HDV is a viral infection that causes liver inflammation, sometimes leading to serious liver damage. It is caused by the hepatitis D virus (HDV) and is considered to be the most severe form of viral hepatitis in humans due to more rapid progression toward liver-related death and hepatocellular carcinoma. HDV requires the hepatitis B virus (HBV) for its replication. HDV infection occurs as a co-infection or aa s super-infection with HBV.

Simultaneous infection (i.e. co-infection) with HBV and HDV can lead to a mild-to-severe or even fulminant hepatitis, whereas the super-infection of HDV on chronic hepatitis B accelerates progression to a more severe disease in all ages and in 70‒90% of people. HDV affects globally nearly 5% of people who have a chronic infection with HBV, and that HDV coinfection could explain about 1 in 5 cases of liver disease and liver cancer in people with HBV infection.

The severity of hepatitis D is influenced by HDV genotype. There are at least 8 genotypes (genetic variants) of HDV based on 14-38% sequence variation. These genotypes are associated with different long-term outcomes. Genotype 1 chronic HDV super-infection usually leads to a rapid progression to cirrhosis. Genotypes 2 and 4 cause a milder disease over a longer time course whereas genotype 3 is associated with advanced necroinflammatory.

Hepatitis D Market Key Facts
• According to WHO estimates, HDV affects nearly 5% of people globally, who have a chronic infection with hepatitis B virus (HBV). In the 7MM, the total diagnosed prevalent cases of HDV were close to 300,000 in 2022. These cases are expected to grow with a significant CAGR in the study period 2019-2032.
• As per DelveInsight estimates, in 2022, the US, accounted for the highest number of prevalent cases of HDV (nearly 162,000 cases).
• In 2022, there were about 90,000 cases of HDV infection in EU4 and the UK, among which
• Germany accounted for the highest prevalent cases of HDV infection (~29,000 cases) and France showed the lowest number of cases (8,000).
• As per DelveInsight estimates, Japan accounted for close to 38,000 prevalent cases of HDV in 2022.

Discover How Hepatitis D Market Will Grow by 2032:
https://www.delveinsight.com/report-store/hepatitis-d-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Hepatitis D Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Hepatitis D therapies in the market. It also provides a detailed assessment of the Hepatitis D market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the market trend for each marketed Hepatitis D drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Hepatitis D Epidemiology
The epidemiology section covers detailed insights into the historical, and current Hepatitis D patient pool and forecasted epidemiology trends for every seven major countries (7MM) from 2019 to 2032.

The Report Covers the Hepatitis D Epidemiology Segmented as -
• Total Diagnosed Prevalent cases of HDV in the 7MM (2019-2032)
• Age-specific Prevalent Cases of HDV in the 7MM (2019-2032)
• Gender-specific Diagnosed Prevalent Cases of HDV in the 7MM (2019-2032)
• Total Treated Cases of HDV in the 7MM (2019-2032)
• Diagnosed Prevalent Cases of HDV by Impact on Liver in the 7MM (2019-2032)

Get Key Insights Into the Evolving Hepatitis D Epidemiology Trends @
https://www.delveinsight.com/report-store/hepatitis-d-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Hepatitis D Drugs Uptake and Pipeline Development Activities
The drugs' uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatitis D market or expected to be launched during the study period. The analysis covers the market share by Hepatitis D drugs, patient uptake by therapies, and sales of each drug.

The report's drugs uptake section helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It allows the comparison of the drugs based on market share and size, which again will be helpful in investigating factors important in understanding the market dynamics and in making financial and regulatory decisions.

The report also covers the Hepatitis D Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About Ongoing Pipeline Development Activities @
https://www.delveinsight.com/sample-request/hepatitis-d-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Hepatitis D Therapeutics Assessment
Several major pharma and biotech companies are developing therapies for Hepatitis D. Currently, Eiger Biopharmaceuticals is leading the therapeutics market with its Hepatitis D drug candidates in the most advanced stage of clinical development.

Leading Companies in the Hepatitis D Therapeutics Market Include
• Eiger Biopharmaceuticals
• Arrowhead Pharmaceuticals
• Antios Therapeutics
• PharmaEssentia
• REPLICor
• SomaGenics
• Vir Biotechnology
• VLP Biotech
And Many Others

Emerging and Marketed Hepatitis D Therapies Covered in the Report Include
• Lonafarnib: Eiger Biopharmaceuticals
• JNJ 73763989: Arrowhead Pharmaceuticals
• HEPCLUDEX (bulevirtide): Gilead Sciences
• JNJ-73763989/JNJ-3989: Janssen Research & Development, LLC
And Many More

Learn More About the Emerging Therapies & Key Companies in the Hepatitis D Therapeutics Market:
https://www.delveinsight.com/sample-request/hepatitis-d-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Hepatitis D Competitive Intelligence Analysis
4. Hepatitis D Market Overview at a Glance
5. Hepatitis D Background and Overview
6. Hepatitis D Patient Journey
7. Hepatitis D Epidemiology and Patient Population
8. Hepatitis D Treatment Algorithm, Current Treatment, and Medical Practices
9. Hepatitis D Unmet Needs
10. Key Endpoints of Hepatitis D Treatment
11. Hepatitis D Marketed Products
12. Hepatitis D Emerging Therapies
13. Hepatitis D Seven Major Market Analysis
14. Attribute Analysis
15. Hepatitis D Market Outlook (7 major markets)
16. Hepatitis D Access and Reimbursement Overview
17. KOL Views on the Hepatitis D Market.
18. Hepatitis D Market Drivers
19. Hepatitis D Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/hepatitis-d-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Anti-hypertension Market
https://www.delveinsight.com/report-store/anti-hypertension-market

Lower-Limb Spasticity Market
https://www.delveinsight.com/report-store/lower-limb-spasticity-market

Glioblastoma Market
https://www.delveinsight.com/report-store/glioblastoma-market

Cancer Cachexia (CC) Market
https://www.delveinsight.com/report-store/cancer-cachexia-cc-market-insights

Hepatitis C Market
https://www.delveinsight.com/report-store/hepatitis-c-market

Open-Angle Glaucoma Market
https://www.delveinsight.com/report-store/open-angle-glaucoma-market

Gastroesophageal Reflux Disease (GERD) Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market

Duchenne Muscular Dystrophy Market
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market

Helicobacter Pylori Infections Market
https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market

Cerebral Infarction Market
https://www.delveinsight.com/report-store/cerebral-infarction-market

Gastroesophageal Reflux Disease (GERD) Market
https://www.delveinsight.com/report-store/gastroesophageal-reflux-disease-gerd-market

Papilloma Market
https://www.delveinsight.com/report-store/papilloma-market

Peripheral Neuritis Market
https://www.delveinsight.com/report-store/peripheral-neuritis-market

Renal Insufficiency Market
https://www.delveinsight.com/report-store/renal-insufficiency-market

Dysthymia Market
https://www.delveinsight.com/report-store/dysthymia-market

Persistent Depressive Disorder Market
https://www.delveinsight.com/report-store/persistent-depressive-disorder-market

Relapsing Multiple Sclerosis (RMS) Market
https://www.delveinsight.com/report-store/relapsing-multiple-sclerosis-rms-market

Asthma Market
https://www.delveinsight.com/report-store/asthma-market

Helicobacter Pylori Infections Market
https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market

Corneal Dystrophy Market
https://www.delveinsight.com/report-store/corneal-dystrophy-market

Peripheral Vascular Devices Global Market
https://www.delveinsight.com/report-store/peripheral-vascular-devices-market

Physiotherapy Equipment Market Concussions Market
https://www.delveinsight.com/report-store/concussions-market

Herpes Simplex Market
https://www.delveinsight.com/report-store/herpes-simplex-market

Hairy Cell Leukemia (HCL) Market
https://www.delveinsight.com/report-store/hairy-cell-leukemia-hcl-market

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.